Summary Endurance time on submaximal exercise tests is a sensitive measure in detecting changes after medical intervention and is used as an outcome in clinical trials, although there has been little discussion regarding the appropriate intensity. Therefore, we investigated whether there were differences in exercise responses between endurance tests at high versus moderate intensity, and analyzed which test was more appropriate.
Introduction
Exercise capacity has become an important clinical outcome measure in patients with chronic obstructive pulmonary disease (COPD), in addition to airflow limitation evaluated by forced expiratory volume in 1 s (FEV 1 ), because exercise capacity is difficult to predict from resting pulmonary function 1 and can be the most significant predictor of mortality in COPD. 2 Several methods for evaluating exercise capacity have been developed, including a 6-min walking test, progressive exercise testing and a submaximal endurance test, using a cycle ergometer or treadmill.
Among some indices of exercise capacity, exercise endurance time has recently begun to be used in clinical trials. 3 It has been demonstrated to be more sensitive in detecting the changes after bronchodilator administration than either walking distance or peak oxygen uptake ' V O 2 in patients with COPD. 4 O'Donnell et al. 5 similarly reported that the endurance time was reliable, being both reproducible and responsive to changes in COPD. Therefore, direct measurement of endurance time is recommended in clinical trials to avoid underestimation of the true clinical benefits by relying too heavily on changes in FEV 1 to assess therapeutic efficacy.
There are, however, no standard protocols for sub-maximal endurance testing; the appropriate intensity of exercise for endurance testing is a subject for discussion. Therefore, in the present study, we proposed to investigate whether there would be any differences in exercise responses between the two different exercise procedures at high versus moderate intensity, and to analyze which test would be more appropriate in clinical trials.
Methods Patients
We recruited 67 consecutive patients with clinically stable COPD, as defined by the American Thoracic Society (ATS), 7 to investigate the effects of inhaled b 2 -agonists (salbutamol) and anticholinergic agents (ipratropium bromide) on exercise endurance between January 1999 and December 2001. 8 Among these patients, 37 agreed to participate in the present additional study to compare exercise responses during high versus moderate intensities of endurance exercise. Entry criteria for the present study were: (1) age over 50 years; (2) a smoking history of more than 20 pack-years; (3) FEV 1 of less than 80% of the predicted value; and (4) best post-bronchodilator FEV 1 /forced vital capacity (FVC) of less than 0.7. Exclusion criteria included: (1) an exacerbation of airflow limitation within the last 3 months; (2) a history of asthma; (3) other diseases likely to affect exercise; (4) severe hypoxemia defined as an arterial oxygen tension (PaO 2 ) less than 8 kPa at rest; and (5) treatment with oral bronchodilators, and oral or inhaled corticosteroids over the preceding 4 weeks. Written informed consent was obtained from all patients before the study.
All subjects underwent baseline pulmonary function testing at least 12 h after the withdrawal of bronchodilators. In accordance with the method described by the ATS 9 , spirometric testing for determining FEV 1 and FVC was performed using a spirometer (AUTOSPIRO AS-600, Minato Medical Science Co. Ltd., Osaka, Japan) which was calibrated with a 3.0-l syringe. The largest FEV 1 and FVC values from three maneuvers were then analyzed. The residual volume (RV) was measured by the closed-circuit helium method, and the carbon monoxide transfer coefficient (K CO ) was measured by the single-breath technique (CHES-TAC-65V, Chest, Tokyo, Japan). Predicted values for the pulmonary function indices were calculated according to the recommendations of the Japan Society of Chest Diseases 10 .
Exercise tests
The symptom-limited progressive exercise test was performed on a calibrated, electrically braked cycle ergometer (Corival WLP-400, Lode, Groningen, The Netherlands) 4 . Subjects breathed through a low resistance unidirectional valve (Rudolph Face Mask Exercise Testing, Hans Rudolph Inc., Kansas City, USA) attached to their face mask. Exercise data were recorded using an automated exercise testing system (Desktop Diagnostics/CPX, Medical Graphic Corporation, St. Paul, USA) which converts the breath-by-breath analog input into a digital form on-line. The minute ventilation ( ' V E ) and oxygen and carbon dioxide tension in the expired air were determined every eight breaths, and the mean ' V E ; ' V O 2 and carbon dioxide output ' V CO 2 were then calculated. The gas analyzer was calibrated just before the study with air and a standard reference gas mixture (15% oxygen, 5% carbon dioxide). Patients began unloaded cycling for 3 min, after which the power output was increased progressively by increments of 1 W every 3 sec to the limit of tolerance. The arterial oxygen saturation Sa O 2 was measured continuously by pulse oximetry (N-200 pulse oximeter, Nellcor Inc., Hayward, USA), and the heart rate (HR) by electrocardiography (Life Scope 8, Nihon Koden Co., Tokyo, Japan). During exercise, symptoms of breathlessness were scored with the Borg scale (0-10), 11 which was presented on the board within easy view of the patients. They rated their perceived level of breathlessness by pressing an electronic button whenever they felt a change in the severity of their breathlessness. The maximum work rate (W max ) was defined as the highest work level that was reached. Similarly, peak ' V O 2 ; peak ' V CO 2 and peak ' V E were the highest levels reached during exercise.
Sub-maximal endurance tests were performed on the cycle ergometer at 80% (high intensity) and 60% (moderate intensity) of the W max reached on the progressive cycle ergometry. After unloaded pedaling for 3 min, the power output was increased to that work level. The patients continued cycling at the constant workload until the test was stopped according to the same criteria as used for progressive cycle ergometry, and the endurance time was then recorded. Borg scores during exercise were also recorded as recorded for progressive cycle ergometry.
Study design
During the initial screening, the subjects practiced progressive cycle ergometry on at least two occasions, and were familiarized with rating breathlessness using the Borg score 11 during exercise. Exercise tests were performed around the same time on seven separate days over a 2-week period. Inhaled bronchodilators were not used for at least 12 h before starting each test day.
On day 1, symptom-limited progressive cycle ergometry was performed, and then the individual W max was determined as the highest work level reached. This was performed at 60 min after inhaling 400 mg (4 puffs) of salbutamol plus 80 mg (4 puffs) of ipratropium bromide using a metereddose inhaler (MDI) with a spacer device (InspirEaset, Schering-Plough K.K., Osaka, Japan) 12 . On at least one occasion between days 1 and 2, subjects practiced the cycle endurance test at a constant work rate of 80% of the W max reached on day 1.
On days 2-4 and 5-7, the cycle endurance tests were performed at 80% (80% test) and 60% (60% test) of the W max on progressive cycle ergometry, respectively. During each 3-day period, tests were performed at 40 min after inhaling 400 mg (4 puffs) of salbutamol, 80 mg (4 puffs) of ipratropium bromide or an identical placebo in a randomized, double-blind, cross-over fashion. The spirometric parameters were then assessed before and at 30 and 60 min after inhalation. Prior to each spirometric measurement, the pulse rate and blood pressure were measured after at least 5 min of rest.
Statistical analysis
Results are expressed as mean7SD, unless otherwise stated. Comparisons of the values between the different exercise tests and between placebo and bronchodilators were performed by a two-tailed paired-t-test (parametric data) or a Wilcoxon signed rank test (nonparametric data). When comparing the variability of the endurance time at different exercise settings, the coefficient of variation was calculated by expressing the standard deviation as a percentage of the mean. Relationships between two sets of data were analyzed by Spearman's correlation coefficient test. A P-value of less than 0.05 was considered to be statistically significant.
Results
The baseline characteristics of the 37 COPD patients enrolled in the study are presented in Table 1 . Their age averaged 70.875.7 years, and their average FEV 1 was 1.2470.44 l (47.5716.0%pre-dicted). Mild to severe COPD patients were included in the study. Two patients were dropped from the study due to acute exacerbation of COPD and knee pain, respectively, during the moderate intensity (60%) exercise endurance tests, and 35 completed the study.
Physiologic data on the endurance tests at 80% and 60% of the W max are presented in Table 2 . The endurance time was much shorter at 80% of the W max than at 60% (Po0:001). The coefficients of variation were 53.8 (placebo), 57.6 (salbutamol) and 50.5 (ipratropium bromide) in the 80% test, and 84.0, 76.6 and 84.6, respectively, in the 60% test. In addition, salbutamol and ipratropium bromide produced significant improvements by 22 s (P ¼ 0:02) and 21 s (P ¼ 0:007) in comparison to the placebo in the 80% test. However, these improvements did not reach statistical significance in the 60% test (P ¼ 0.07 and 0.06, respectively). Fig. 1 shows the difference in endurance time between bronchodilators and placebo for each exercise intensity.
The endurance time after placebo was strongly correlated between the 80% and 60% exercise tests (Spearman's correlation coefficients [r s ] ¼ 0.71, Po0:001). However, the change in the endurance time between salbutamol and placebo in the 80% test was not significantly correlated with the change in the endurance time between salbutamol and placebo in the 60% test (r s ¼ À0:09; P ¼ 0:58). This lack of correlation was similarly observed between ipratropium bromide and placebo (r s ¼ 0:03; P ¼ 0:87). Peak ' V O 2 ; peak ' V CO 2 and peak ' V E tended to be higher in the 80% test (Table 2 ). In contrast, the peak Borg score was somewhat higher in the 60% test. There were no significant differences in peak heart rates and minimal SaO 2 between 80% and 60% tests, except for the peak heart rate after ipratropium bromide. Fig. 2 shows the Borg scores over time after placebo during cycle endurance tests at 80% and 60% of the W max in patients with COPD. Dyspnoea continued to increase from the start to the peak level in the 80% test. However, in the 60% test, the increase in dyspnoea was slow, especially after 6 min. 
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Discussion
We demonstrated that the endurance time in the high intensity (80%) exercise test was much shorter than in the moderate intensity (60%) exercise test. We also found that the variability in endurance time as evaluated by the coefficients of variation was less in the 80% test than in the 60% test. Moreover, the endurance time was more sensitive in detecting changes after administration of salbutamol or ipratropium bromide during the 80% test. Therefore, we conclude that the high intensity endurance test will be more favorable in clinical trials than the moderate intensity endurance test, when using the endurance time as an outcome measure of exercise capacity. Endurance time has been reported to be a more sensitive measure of exercise capacity than the 6-min walking distance or peak ' V O 2 on incremental tests in detecting changes after bronchodilator administration, 4 in pulmonary rehabilitation program [13] [14] [15] [16] or with oxygen therapy. 17 Therefore, endurance time is used as an outcome measure of exercise capacity, because a higher response index allows clinical trials to be performed with fewer candidates. Presently, however, there are no standard protocols for sub-maximal endurance testing. Most notably, there has been little discussion regarding the most appropriate intensity of exercise during endurance testing.
Previously, we compared different exercise performance tests in evaluating the effects of oxitropium bromide on exercise capacity, and found that the endurance time when tests were performed at 80% of the W max was a responsive measure, 4 as was also demonstrated in the present study. A recent large-scale study to investigate the effects of tiotropium bromide on exercise capacity in 187 COPD patients was performed using steady-state cycle ergometry at 75% maximum work rate. 3 Other studies [13] [14] [15] [16] [17] have used high intensity endurance tests at more than 75% of the W max ; and have demonstrated positive effects of medical interventions on endurance time. Shorter exercise endurance tests performed at high intensity are beneficial in evaluating exercise capacity in patients with COPD, because these tests are practical to apply but also prevent the patients from stopping exercise due to psychological reasons such as a loss of motivation.
On the endurance test at 60% of the W max in the present study, the improvements in the endurance time after bronchodilators did not reach statistically significant differences. In addition, in the present study, there were 6 patients who cycled more than 20 min once, although the mean endurance time was around 9-10 min. In another study, 18 COPD subjects with a mean FEV 1 of 1.68 l and 50% predicted had no difficulty in sustaining endurance exercise at 50% of the W max for 20 min, although their mean endurance time at 75% of the W max was only about 6 min. Although both the variability evaluated as the coefficient of variation and the range of differences in endurance time following bronchodilators (Fig. 1) were greater in the 60% test, these might have been due to the longer exercise time.
Exercise duration time with incremental exercise testing has been recommended to be about 10 min. 19, 20 Franco et al. 21 also selected 10 min as the total duration of sub-maximal exercise endurance, because metabolic and physiologic responses usually reach a plateau within 5-10 min of exertion at a constant work load. In addition, the duration of exertion may influence perceptual responses. 21 It is interesting in the present study that, although the peak physiologic exercise indices evaluated by ' V O 2 ; ' V CO 2 and ' V E were lower in the moderate intensity exercise tests, as predicted based on past reports, 18 ,21 patients rated rather higher peak Borg scores. According to Fig. 2 , with moderate intensity exercise, dyspnoea peaked at approximately 6 min, after which the monotony of exercise might have affected the slight increase in dyspnoea. Therefore, endurance testing lasting more than 10 min at moderate or low intensity might be less favorable when using endurance time as an outcome.
In the present study, the endurance time after placebo at 80% of the W max was strongly correlated to that at 60% of the W max : However, the difference in the endurance time between placebo and bronchodilators at 80% was not significantly correlated with that at 60%. One reason for this observation may be that exercise limitations differed between high and moderate intensity endurance tests. Therefore, the effects of bronchodilators on the endurance time might have been detected differentially. Although exercise limitation is diverse, peripheral muscular fatigue, in addition to ventilatory and gas-exchange limitations, is considered to be a main contributor in COPD. 22, 23 As an expected weakness, high intensity exercise would put a greater load on patients' legs, and cycle ergometry involves strictly local leg exercise, rather than whole body exercise, although we did not evaluate breathlessness and leg fatigue separately as a limitation of the present study. On the other hand, prolonged constant exercise at moderate intensity exercise may affect patients psychologically due to boredom and so on.
ARTICLE IN PRESS
Some limitations of the present study should be mentioned. First, although the significant improvements in the endurance time were detected on the high intensity tests, their changes might be small in absolute terms. How they are reflected in daily activities of patients with COPD remains to be investigated, although we previously examined the relationship between the cycle endurance time, and other measures of exercise capacity, pulmonary function, dyspnoea and health-related quality of life. 24 For the sub-maximal exercise testing to be used more as an outcome measure, the minimum clinically important difference should be established. Second, we did not calculate the lactic threshold as an outcome measure in the present study. Therefore, we cannot present any data on how many patients exercised below their lactic threshold although it is possible that some patients might do so especially on the moderate intensity tests. Such a detailed analysis should be performed in the future. Third, the reasons for stopping exercise might be different between the mild to moderate and the severe COPD patients. Therefore, separate analyses between them might have revealed more information, although we did not do this due to the small sample size in the present study.
In the present study, we compared the endurance test results between 80% and 60% of the W max : When the endurance time is used as an outcome measure of exercise capacity, we recommend that high intensity endurance exercise is preferable to moderate intensity exercise, because the shorter duration of exercise is more practical, and the results are less variable and more sensitive in detecting changes after medical intervention.
